Nerve-sparing radical hysterectomy versus conventional radical hysterectomy in early-stage cervical cancer. A systematic review and meta-analysis of survival and quality of life

被引:32
作者
van Gent, M. D. J. M. [1 ]
Romijn, L. M. [2 ]
van Santen, K. E. [2 ]
Trimbos, J. B. M. Z. [1 ]
de Kroon, C. D. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Gynaecol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Med Ctr Haaglanden Bronovo, Dept Gynaecol, Lijnbaan 32, NL-2512 VA The Hague, Netherlands
关键词
Cervical cancer; Nerve-sparing; Safety; Survival; Quality of life; POSTSURGICAL BLADDER FUNCTION; RANDOMIZED CONTROLLED-TRIAL; NEOADJUVANT CHEMOTHERAPY; PELVIC LYMPHADENECTOMY; FUNCTION RECOVERY; FOLLOW-UP; OUTCOMES; CARCINOMA; FEASIBILITY; RESECTION;
D O I
10.1016/j.maturitas.2016.08.005
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background and aims: Survival after radical hysterectomy (RH) for early-stage cervical cancer is good. Hence quality of life (QOL) after treatment is an important issue. Nerve-sparing radical hysterectomy (NSRH) improves QOL by selectively sparing innervation of bladder, bowel and vagina, reducing therapy induced morbidity. However, the oncological outcome and the functional outcome after NSRH are subjects of debate. We aim to present the best possible evidence available regarding both QOL and survival after NSRH in early-stage cervical cancer. Methods: Systematic review and meta-analysis on studies comparing NSRH and RH. Results: Forty-one studies were included, and 27 were used for the meta-analysis. There was no difference in 2-, 3- and 5-year overall survival: the risk ratios (RRs) were respectively 1.02 (95% CI 0.99-1.05, n = 879), 1.01 (95% CI 0.95-1.08, n = 1324) and 1.03 (95% CI 0.99-1.08, n = 638). No difference was found in 2-, 3 and 5-year disease-free survival: RR 1.01 (95% CI 0.95-1.05, n = 1175), 0.99 (95% CI 0.94-1.03, n =1130) and 1.00 (95% CI 0.95-1.06, n = 933) respectively. Post-operative time to micturition was significantly shorter in the NSRH group: standardized mean difference (SMD) -0.84 (CI 95% -1.07 to -0.60). Conclusions: NSRH can be considered safe and effective for early-stage cervical cancer since short- and long-term survival do not differ from those of conventional RH, while bladder function after NSRH is significantly less impaired. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 70 条
  • [1] A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery
    Angioli, Roberto
    Plotti, Francesco
    Aloisi, Alessia
    Scaletta, Giuseppe
    Capriglione, Stella
    Luvero, Daniela
    Fiore, Laura
    Terranova, Corrado
    Montera, Roberto
    Panici, Pierluigi Benedetti
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 433 - 438
  • [2] Worldwide burden of cervical cancer in 2008
    Arbyn, M.
    Castellsague, X.
    de Sanjose, S.
    Bruni, L.
    Saraiya, M.
    Bray, F.
    Ferlay, J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (12) : 2675 - 2686
  • [3] ASMUSSEN M, 1987, ZBL GYNAKOL, V109, P222
  • [4] Oncological Outcomes of Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Systematic Review
    Basaran, Derman
    Dusek, Ladislav
    Majek, Ondrej
    Cibula, David
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (09) : 3033 - 3040
  • [5] Standards for Patient-Reported Outcome-Based Performance Measures
    Basch, Ethan
    Torda, Phyllis
    Adams, Karen
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (02): : 139 - 140
  • [6] Vaginal changes and sexuality in women with a history of cervical cancer
    Bergmark, K
    Åvall-Lundqvist, E
    Dickman, PW
    Henningsohn, L
    Steineck, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (18) : 1383 - 1389
  • [7] Bogani G., 2014, J SEX MED
  • [8] Nerve-Sparing Versus Conventional Laparoscopic Radical Hysterectomy A Minimum 12 Months' Follow-up Study
    Bogani, Giorgio
    Cromi, Antonella
    Uccella, Stefano
    Serati, Maurizio
    Casarin, Jvan
    Pinelli, Ciro
    Nardelli, Federica
    Ghezzi, Fabio
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (04) : 787 - 793
  • [9] Ceccaroni M, 2012, ANTICANCER RES, V32, P581
  • [10] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579